Turajlic S - Search Results

1

Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma.

Lim KHJ, Spain L, Barker C, Georgiou A, Walls G, Gore M, Turajlic S, Board R, Larkin JM, Lorigan P. Lim KHJ, et al. Among authors: turajlic s. ESMO Open. 2018 Feb 24;3(2):e000317. doi: 10.1136/esmoopen-2017-000317. eCollection 2018. ESMO Open. 2018. PMID: 29531842 Free PMC article.

2

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R. Girotti MR, et al. Among authors: turajlic s. Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14. Cancer Discov. 2013. PMID: 23242808 Free PMC article.

3

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Khattak M, Fisher R, Turajlic S, Larkin J. Khattak M, et al. Among authors: turajlic s. Ther Adv Med Oncol. 2013 Mar;5(2):105-18. doi: 10.1177/1758834012466280. Ther Adv Med Oncol. 2013. PMID: 23450149 Free PMC article.

4

Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.

Furney SJ, Turajlic S, Stamp G, Nohadani M, Carlisle A, Thomas JM, Hayes A, Strauss D, Gore M, van den Oord J, Larkin J, Marais R. Furney SJ, et al. Among authors: turajlic s. J Pathol. 2013 Jul;230(3):261-9. doi: 10.1002/path.4204. J Pathol. 2013. PMID: 23620124

5

Phase I/II RAF kinase inhibitors in cancer therapy.

Turajlic S, Ali Z, Yousaf N, Larkin J. Turajlic S, et al. Expert Opin Investig Drugs. 2013 Jun;22(6):739-49. doi: 10.1517/13543784.2013.797964. Epub 2013 May 6. Expert Opin Investig Drugs. 2013. PMID: 23642225 Review.

6

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J, Marais R. Turajlic S, et al. Ann Oncol. 2014 May;25(5):959-67. doi: 10.1093/annonc/mdu049. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504448 Free PMC article.

7

BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling.

Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, Larkin J, Lorigan P, Cook M, Springer C, Marais R. Sanchez-Laorden B, et al. Among authors: turajlic s. Sci Signal. 2014 Mar 25;7(318):ra30. doi: 10.1126/scisignal.2004815. Sci Signal. 2014. PMID: 24667377

8

The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.

Furney SJ, Turajlic S, Stamp G, Thomas JM, Hayes A, Strauss D, Gavrielides M, Xing W, Gore M, Larkin J, Marais R. Furney SJ, et al. Among authors: turajlic s. Pigment Cell Melanoma Res. 2014 Sep;27(5):835-8. doi: 10.1111/pcmr.12279. Epub 2014 Jun 30. Pigment Cell Melanoma Res. 2014. PMID: 24913711

9

How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?

Soultati A, Stares M, Swanton C, Larkin J, Turajlic S. Soultati A, et al. Among authors: turajlic s. Curr Opin Urol. 2015 Sep;25(5):358-66. doi: 10.1097/MOU.0000000000000204. Curr Opin Urol. 2015. PMID: 26125509 Review.

10

Academically led clinical trials: challenges and opportunities.

Turajlic S, Larkin J, Swanton C. Turajlic S, et al. Ann Oncol. 2015 Oct;26(10):2010-1. doi: 10.1093/annonc/mdv332. Epub 2015 Aug 3. Ann Oncol. 2015. PMID: 26240217 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters